Literature DB >> 15502130

Is the subthalamic nucleus hypointense on T2-weighted images? A correlation study using MR imaging and stereotactic atlas data.

Didier Dormont1, Kenneth G Ricciardi, Dominique Tandé, Karine Parain, Carole Menuel, Damien Galanaud, Soledad Navarro, Philippe Cornu, Yves Agid, Jérôme Yelnik.   

Abstract

BACKGROUND AND
PURPOSE: Although the subthalamic nucleus is the most frequently used target for surgical treatment of Parkinson's disease, the criteria on which it can be identified on T2-weighted images have never been clearly defined. This study was conducted to characterize the precise anatomic distribution of T2-weighted hyposignal in the subthalamic region and to correlate this hyposignal with iron content in the subthalamic nucleus.
METHODS: The T2-weighted MR imaging acquisitions of 15 patients with Parkinson's disease were fused with a digitized version of the Schaltenbrand and Wahren anatomic atlas. The MR signal intensity within the anatomic limits of the subthalamic nucleus was evaluated. An anatomic specimen obtained at autopsy was used to evaluate iron content.
RESULTS: In all patients, the subthalamic nucleus was hypointense on both sides in the anterior half of the nucleus. At more posterior levels of the nucleus, hypointensity was less frequently observed (20-80%). Hypointensity was never observed at the most posterior pole. Iron was present in the anteromedial part of the nucleus but absent at the most posterior levels.
CONCLUSION: The hypointense signal intensity located lateral to the red nucleus and dorsolateral to the substantia nigra correlates with the presence of iron and corresponds anatomically to the subthalamic nucleus. It can therefore be used as a landmark for electrode implantation in patients with Parkinson's disease. It should, however, be emphasized that although hypointensity was always present in the anterior half of the subthalamic nucleus, the posterior part of the nucleus was not visible in most cases. Copyright American Society of Neuroradiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502130      PMCID: PMC7976405     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  37 in total

1.  Magnetic resonance imaging versus computed tomography for target localization in functional stereotactic neurosurgery.

Authors:  P E Holtzheimer; D W Roberts; T M Darcey
Journal:  Neurosurgery       Date:  1999-08       Impact factor: 4.654

Review 2.  Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease.

Authors:  P Riederer; A Dirr; M Goetz; E Sofic; K Jellinger; M B Youdim
Journal:  Ann Neurol       Date:  1992       Impact factor: 10.422

3.  Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease.

Authors:  L V Laitinen; A T Bergenheim; M I Hariz
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

4.  Computerized tomography (CT) is just as accurate as ventriculography for functional stereotactic thalamotomy.

Authors:  R R Tasker; J O Dostrovsky; E J Dolan
Journal:  Stereotact Funct Neurosurg       Date:  1991       Impact factor: 1.875

5.  Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T.

Authors:  S Aoki; Y Okada; K Nishimura; A J Barkovich; B O Kjos; R C Brasch; D Norman
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

6.  Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla.

Authors:  R J Ordidge; J M Gorell; J C Deniau; R A Knight; J A Helpern
Journal:  Magn Reson Med       Date:  1994-09       Impact factor: 4.668

7.  Topographical and cytological localization of iron in rat and monkey brains.

Authors:  C Francois; J Nguyen-Legros; G Percheron
Journal:  Brain Res       Date:  1981-06-29       Impact factor: 3.252

8.  Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance.

Authors:  B P Bejjani; D Dormont; B Pidoux; J Yelnik; P Damier; I Arnulf; A M Bonnet; C Marsault; Y Agid; J Philippon; P Cornu
Journal:  J Neurosurg       Date:  2000-04       Impact factor: 5.115

9.  Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position.

Authors:  Jürgen Voges; Jens Volkmann; Niels Allert; Ralph Lehrke; Athanasios Koulousakis; Hans-Joachim Freund; Volker Sturm
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

10.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

Authors:  D T Dexter; A Carayon; F Javoy-Agid; Y Agid; F R Wells; S E Daniel; A J Lees; P Jenner; C D Marsden
Journal:  Brain       Date:  1991-08       Impact factor: 13.501

View more
  49 in total

1.  Internal structures of the globus pallidus in patients with Parkinson's disease: evaluation with quantitative susceptibility mapping (QSM).

Authors:  Satoru Ide; Shingo Kakeda; Issei Ueda; Keita Watanabe; Yu Murakami; Junji Moriya; Atsushi Ogasawara; Koichiro Futatsuya; Toru Sato; Norihiro Ohnari; Kazumasa Okada; Atsuji Matsuyama; Hitoshi Fujiwara; Masanori Hisaoka; Sadatoshi Tsuji; Tian Liu; Yi Wang; Yukunori Korogi
Journal:  Eur Radiol       Date:  2014-11-01       Impact factor: 5.315

2.  Direct visualization of the subthalamic nucleus and its iron distribution using high-resolution susceptibility mapping.

Authors:  Andreas Schäfer; Birte U Forstmann; Jane Neumann; Sam Wharton; Alexander Mietke; Richard Bowtell; Robert Turner
Journal:  Hum Brain Mapp       Date:  2011-09-20       Impact factor: 5.038

3.  Aging and inhibitory control of action: cortico-subthalamic connection strength predicts stopping performance.

Authors:  James P Coxon; Annouchka Van Impe; Nicole Wenderoth; Stephan P Swinnen
Journal:  J Neurosci       Date:  2012-06-13       Impact factor: 6.167

4.  Mapping Go-No-Go performance within the subthalamic nucleus region.

Authors:  Tamara Hershey; Meghan C Campbell; Tom O Videen; Heather M Lugar; Patrick M Weaver; Johanna Hartlein; Morvarid Karimi; Samer D Tabbal; Joel S Perlmutter
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

5.  Optimal MRI methods for direct stereotactic targeting of the subthalamic nucleus and globus pallidus.

Authors:  Ruth L O'Gorman; Karin Shmueli; Keyoumars Ashkan; Michael Samuel; David J Lythgoe; Asal Shahidiani; Stephen J Wastling; Michelle Footman; Richard P Selway; Jozef Jarosz
Journal:  Eur Radiol       Date:  2010-07-21       Impact factor: 5.315

6.  Role of the basal ganglia and frontal cortex in selecting and producing internally guided force pulses.

Authors:  David E Vaillancourt; Hong Yu; Mary A Mayka; Daniel M Corcos
Journal:  Neuroimage       Date:  2007-03-13       Impact factor: 6.556

7.  Cortical and subcortical contributions to Stop signal response inhibition: role of the subthalamic nucleus.

Authors:  Adam R Aron; Russell A Poldrack
Journal:  J Neurosci       Date:  2006-03-01       Impact factor: 6.167

8.  Effects of visual and auditory feedback on sensorimotor circuits in the basal ganglia.

Authors:  Janey Prodoehl; Hong Yu; Pooja Wasson; Daniel M Corcos; David E Vaillancourt
Journal:  J Neurophysiol       Date:  2008-02-20       Impact factor: 2.714

9.  Three-dimensional fluid-attenuated inversion recovery sequence for visualisation of subthalamic nucleus for deep brain stimulation in Parkinson's disease.

Authors:  Young Jin Heo; Sang Joon Kim; Ho Sung Kim; Choong Gon Choi; Seung Chai Jung; Jung Kyo Lee; Chong Sik Lee; Sun J Chung; So Hyun Cho; Gyoung Ro Lee
Journal:  Neuroradiology       Date:  2015-07-09       Impact factor: 2.804

10.  Region of interest template for the human basal ganglia: comparing EPI and standardized space approaches.

Authors:  Janey Prodoehl; Hong Yu; Deborah M Little; Ivy Abraham; David E Vaillancourt
Journal:  Neuroimage       Date:  2007-09-22       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.